Article: Broad cross-protection against H5N1 avian influenza virus infection by means of monoclonal antibodies that map to conserved viral epitopes

File Download Links for fulltext
(May Require Subscription)
Supplementary
  • Basic View
  • Metadata View
  • XML View
TitleBroad cross-protection against H5N1 avian influenza virus infection by means of monoclonal antibodies that map to conserved viral epitopes
AuthorsChen, Y1 2
Qin, K2
Wai, LW2
Li, G1
Zhang, J1
Du, H1
Mun, HN1
Shih, JWK1
Peiris, JSM2
Guan, Y2 3
Chen, H2 3
Xia, N1
Issue Date2009
PublisherOxford University Press. The Journal's web site is located at http://jid.oxfordjournals.org
CitationJournal Of Infectious Diseases, 2009, v. 199 n. 1, p. 49-58 [How to Cite?]
DOI: http://dx.doi.org/10.1086/594374
AbstractBackground. Passive immunization with human H5 antisera or H5-specific monoclonal antibodies (MAbs) has potential as an effective treatment for acute H5N1 influenza virus infection, but its efficacy against antigenically diverse H5N1 viruses is unconfirmed. Methods. Cross-protection against antigenically diverse H5N1 strains with H5-specific MAbs, generated by successive immunization of antigenically distinct strains, was evaluated in mice. Results. A panel of 52 broadly cross-reactive H5 specific MAbs were generated and characterized. One of these MAbs, 13D4, has been demonstrated to protect mice against lethal challenge by 4 H5N1 strains representing the current major genetic populations, clades 1, 2.1, 2.2, and 2.3, even at a stage of infection when H5N1 virus has disseminated beyond the pulmonary system. Complete neutralization of virus in lung tissue of infected animals was observed 24 h after treatment with 13D4. Mapping of this MAb with escape mutants showed it to bind to 2 conserved, possibly critical, sites of H5N1 hemagglutinin, 152 and 182. Conclusion. Generation of broadly cross-protective MAbs against H5N1 influenza virus may be optimized by selecting MAbs that target conserved sites in hemagglutinin. H5 MAbs such as 13D4 may prove to have therapeutic value in controlling infection due to current and future H5N1 variants. © 2008 by the Infectious Diseases Society of America. All rights reserved.
ISSN0022-1899
2011 Impact Factor: 6.41
2011 SCImago Journal Rankings: 0.831
DOIhttp://dx.doi.org/10.1086/594374
ISI Accession Number IDWOS:000261754400008
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorChen, Y
dc.contributor.authorQin, K
dc.contributor.authorWai, LW
dc.contributor.authorLi, G
dc.contributor.authorZhang, J
dc.contributor.authorDu, H
dc.contributor.authorMun, HN
dc.contributor.authorShih, JWK
dc.contributor.authorPeiris, JSM
dc.contributor.authorGuan, Y
dc.contributor.authorChen, H
dc.contributor.authorXia, N
dc.date.accessioned2012-08-08T08:51:04Z
dc.date.available2012-08-08T08:51:04Z
dc.date.issued2009
dc.description.abstractBackground. Passive immunization with human H5 antisera or H5-specific monoclonal antibodies (MAbs) has potential as an effective treatment for acute H5N1 influenza virus infection, but its efficacy against antigenically diverse H5N1 viruses is unconfirmed. Methods. Cross-protection against antigenically diverse H5N1 strains with H5-specific MAbs, generated by successive immunization of antigenically distinct strains, was evaluated in mice. Results. A panel of 52 broadly cross-reactive H5 specific MAbs were generated and characterized. One of these MAbs, 13D4, has been demonstrated to protect mice against lethal challenge by 4 H5N1 strains representing the current major genetic populations, clades 1, 2.1, 2.2, and 2.3, even at a stage of infection when H5N1 virus has disseminated beyond the pulmonary system. Complete neutralization of virus in lung tissue of infected animals was observed 24 h after treatment with 13D4. Mapping of this MAb with escape mutants showed it to bind to 2 conserved, possibly critical, sites of H5N1 hemagglutinin, 152 and 182. Conclusion. Generation of broadly cross-protective MAbs against H5N1 influenza virus may be optimized by selecting MAbs that target conserved sites in hemagglutinin. H5 MAbs such as 13D4 may prove to have therapeutic value in controlling infection due to current and future H5N1 variants. © 2008 by the Infectious Diseases Society of America. All rights reserved.
dc.description.natureLink_to_subscribed_fulltext
dc.identifier.citationJournal Of Infectious Diseases, 2009, v. 199 n. 1, p. 49-58 [How to Cite?]
DOI: http://dx.doi.org/10.1086/594374
dc.identifier.citeulike3702994
dc.identifier.doihttp://dx.doi.org/10.1086/594374
dc.identifier.epage58
dc.identifier.isiWOS:000261754400008
dc.identifier.issn0022-1899
2011 Impact Factor: 6.41
2011 SCImago Journal Rankings: 0.831
dc.identifier.issue1
dc.identifier.pmid19032063
dc.identifier.scopuseid_2-s2.0-58749101350
dc.identifier.spage49
dc.identifier.urihttp://hdl.handle.net/10722/157539
dc.identifier.volume199
dc.languageeng
dc.publisherOxford University Press. The Journal's web site is located at http://jid.oxfordjournals.org
dc.publisher.placeUnited States
dc.relation.ispartofJournal of Infectious Diseases
dc.relation.referencesReferences in Scopus
dc.subject.meshAnimals
dc.subject.meshAntibodies, Monoclonal - Immunology
dc.subject.meshBirds - Virology
dc.subject.meshBody Weight
dc.subject.meshChick Embryo - Virology
dc.subject.meshConserved Sequence
dc.subject.meshCross Reactions
dc.subject.meshEpitopes - Immunology
dc.subject.meshHemagglutination Inhibition Tests
dc.subject.meshHumans
dc.subject.meshInfluenza A Virus, H5n1 Subtype - Classification - Genetics - Immunology - Isolation & Purification
dc.subject.meshInfluenza Vaccines - Therapeutic Use
dc.subject.meshInfluenza In Birds - Immunology
dc.subject.meshInfluenza, Human - Immunology - Mortality - Pathology
dc.subject.meshMice
dc.subject.meshMice, Inbred Balb C
dc.titleBroad cross-protection against H5N1 avian influenza virus infection by means of monoclonal antibodies that map to conserved viral epitopes
dc.typeArticle
Author Affiliations
  1. Xiamen University
  2. The University of Hong Kong
  3. Shantou University